Dr Najeed Aadil

MBBS, MD,FRCR Clinical Oncology (CO1)
Oncologist | Internationally and nationally awarded in oncology for clinical excellence and research.

[Dr Najeed Aadil @daakhsaab]

The clinical oncology sessions at RCR23 were absolutely amazing. More of such events should be Hybrid as it provides better leaning opportunities for residents from LMICs.

#RCR23 #ClinicalOncology #RadOnc.

[newslaundry @newslaundry]

"Export quality" has no legal definition under Indian food law. It is a market signal. And what it signals is that foreign buyers get tested produce and Indian consumers do not.

@Shardool_ on the food safety gap we have normalised.

https://t.co/6f4NSTMlHN

[Dr Rishabh Jain @DrRishabhOnco]

The ctDNA hype cycle is over.

ASCO’s first ctDNA guideline tells us where liquid biopsy actually changes practice. 🧬

✅ Use ctDNA when:
• Tissue is unavailable or unsafe
• Results are needed urgently
• Drug approvals allow/require liquid biopsy

⚠️ Negative ctDNA does NOT exclude actionable disease.
Tissue confirmation remains critical.

Practice-changing trials cited by ASCO:

🔹 DYNAMIC
Stage II colon cancer
Less chemotherapy, same outcomes.

🔹 PADA-1
ESR1-guided switch to fulvestrant + palbociclib improved PFS.

🔹 SERENA-6
ctDNA-detected ESR1 mutations enabled earlier intervention and significantly prolonged PFS.

🔹 IMvigor011
MRD-positive bladder cancer benefited from adjuvant atezolizumab.

❌ ctDNA should not replace imaging, pathology, or standard staging.

Bottom line:

The question is no longer:
“Can we detect it in blood?”

The question is:
“Will acting on it improve outcomes?”

That’s the bar ASCO has set. 🎯

#Oncology #ctDNA #LiquidBiopsy #ASCO #PrecisionMedicine
@OncoAlert @ASCO @JCOPO_ASCO

[Applied Radiation Oncology @Applied_RadOnc]

Case Study: Craniospinal Irradiation for Leptomeningeal Disease in Recurrent Breast Cancer

🔗 Full details here: https://t.co/YM50eJikKs

LMD is an uncommon complication of breast cancer associated with a poor prognosis. We highlight the challenges of diagnosis and the importance of obtaining an MRI of the entire neuroaxis, cytologic analysis, and correlation with neurological assessment.

#RadOnc #RadiationOncology #CancerCare #CaseStudy #RadOncEd #MedEd

[Obaidullah Baheer @ObaidullaBaheer]

Pakistani military wondering why killing people in Balochistan, Afghanistan and Kashmir isn’t leading to peace.

[Dr Najeed Aadil @daakhsaab]

@AaryanPrateekX In Kashmir they pay 24K/ month, but it is mainly 10 to 12 24 hour shifts

[NonsparseOncologist @5_utr]

@Erman_Akkus TARE is slow, and data for patients who got SBRT bridged to an explant, SBRT historically demonstrates up to a 95% to 100% in-field local control rate during the waiting period.

[Dr Najeed Aadil @daakhsaab]

@KabraVrinda In Kashmir , cardiologists and Gastroenterologists have created a havoc as most of psychiatry patients land with them. I have seen ZERO refferals. Almost every patient on Mirtazepine and Clonezepam

[Dr. Nina Niu Sanford @NiuSanford]

One of most interesting rectal ca studies at #ASCO26

P3 RCT in pMMR LARC: Node-sparing short-course RT + CAPOX + tislelizumab doubled pCR v conventional SCRT + CAPOX (61 v 29%)

Hypothesis = sparing elective node RT preserves antitumor immunity & improves PD1 response @OncoAlert

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[PDBrown @PDBrownOnc]

ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial?
- Upfront RT ↑↑ brain control, no benefit PFS, OS
- Selection criteria high risk (e.g. larger size) for upfront RT is key
https://t.co/1CM31nbxeL

[Dr Rishabh Jain @DrRishabhOnco]

#ASCO26

Axillary dissection may finally be fading into history.

SENOMAC confirms that in patients with clinically node-negative breast cancer and 1-2 SLN macrometastases, omission of completion ALND is non-inferior for overall survival.

🧪 Phase 3 randomized non-inferiority trial
👥 ~2500 patients
🎯 Primary endpoint: OS

Key results:
🔹 5-year OS
• Completion ALND: 93.4%
• Omission ALND: 94.4%

🔹 HR 0.89 (95% CI 0.67-1.17)
✅ Non-inferiority confirmed (p<0.001)

Why this matters:
➡️ Less arm morbidity
➡️ Better QoL & arm function
➡️ Supports further surgical de-escalation

Importantly, most patients also received locoregional RT, so this is de-escalation within a multimodality framework.

Could ALND soon become the exception rather than the rule in early breast cancer?

📖 Presented at #ASCO26

#BreastCancer #OncoTwitter #MedTwitter @OncoAlert @ASCO @myesmo @esmo_open @larvol

[Katy Beckermann @katy_beckermann]

RAD-IO at #ASCO26: durvalumab added to chemoradiation in muscle-invasive bladder cancer cleared its efficacy bar in a bladder-preservation approach. Single-arm, benchmarked against prior CRT data.

Durvalumab given before, during, and 12 months after chemoRT (55Gy/20Fr + 5-FU/mitomycin C). 55 enrolled, 54 treated.

🎯 12-month DFS 80% (40/50), 95% CI 0.67 to 0.89, beating the ≥75% go bar 📊 12-month OS 96%
🔍 But 39% discontinued durvalumab early, toxicity in nearly half. Completing the full adjuvant year is not a given.

Signal suggests further investigation warranted in randomized setting
@Prof_Nick_James #BladderCancer #MIBC #GUonc

[Drew Moghanaki @DrewMoghanaki]

Reminder for those at #ASCO26, local therapy has been previously described as safer than immunotherapy. https://t.co/IIIo9oJyqY

[Balazs Halmos @BalazsHalmosMD]

Another amazing effort by the TATA Memorial team- oncology’s Bollywood stars!

Wait or treat w xrt when facing pts w egfr/alk+ pts upfront w cns mets

Rand ph 3 study (note for pts w measureable disease so not tiny mets and mix of 1st/later gen TKIs) suggests some intracranial but not OS benefits for the upfront xrt approach.

While the data does not settle whether to wait or treat but provides key guidance to clinicians as to proper nuance

Congrats!

[NonsparseOncologist @5_utr]

The precision oncology hype machine just found its new weapon to sell a paradigm. CROWN 7yr lorlatinib. 55% progression-free. Median PFS not reached. Proof the paradigm works. Except it isn’t. Let’s go. 🧵

[Ria Kraft, MD @riakraftmd]

It’s #radonc away rotation season! For #medstudents and junior #residents, here are my go-to resources in radiation oncology (1/2).

[NonsparseOncologist @5_utr]

UniRTX

SBRT + cadonilimab, a PD-1/CTLA-4 bispecific antibody, and lenvatinib as a conversion regimen for potentially resectable HCC

57.7% proceeded to curative intent therapy, all R0, mPFS 18.2 months

0 RILD

#ASCO26

[Priyamvada Maitre @docpriyamvada]

🤩 Finally OUT in @JCO_ASCO!

BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy

A decade of persistence from @VedangMurthy ☺️
@RadOncTMC @TataMemorial @ACTREC_TMC
@PaulSargos
@Xristodouleas

https://t.co/B8iTgImLHr

[Dr Najeed Aadil @daakhsaab]

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer
@VedangMurthy

https://t.co/hroJjWY5tO

[Icro Meattini @Icro_Meattini]

Proud of @CarlottaB presenting #ESTRO26 the 15-year outcomes of the Florence phase III APBI-IMRT trial

With very long-term follow-up, PBI vs WBI showed no detrimental impact on BCSS or OS

A milestone supporting optimisation in early #breastcancer

#OncoAlert @OncoAlert #radonc